Research Article
[Retracted] Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma
Table 5
Univariate analysis of PC effect on REC patients (n (%) and mean ± SD).
| | Factors | n | Effective (n = 27) | Ineffective (n = 32) | χ2/t | |
| | Age (years) | 0.273 | 0.601 | | <65 | 35 | 17 (62.96) | 18 (56.25) | | ≥65 | 24 | 10 (37.04) | 14 (43.75) |
| | Average age (years) | 59 | 63.78 ± 5.30 | 65.02 ± 5.68 | 0.861 | 0.393 |
| | FIGO stage | 1.076 | 0.783 | | I | 35 | 15 (55.56) | 20 (62.50) | | II | 12 | 7 (25.93) | 5 (15.63) | | III | 9 | 4 (14.81) | 5 (15.63) | | IV | 3 | 1 (3.70) | 2 (6.24) |
| | Radiotherapy and chemotherapy after primary surgery | 7.367 | 0.007 | | No | 28 | 18 (66.67) | 10 (31.25) | | Yes | 31 | 9 (33.33) | 22 (68.75) |
| | Infiltrating muscularis | 2.255 | 0.324 | | Without | 11 | 6 (22.22) | 5 (15.63) | | <1/2 | 14 | 4 (14.81) | 10 (31.25) | | ≥1/2 | 34 | 17 (62.97) | 17 (53.12) |
| | Pathological pattern | 2.186 | 0.139 | | Endometrioid adenocarcinoma | 45 | 23 (85.19) | 22 (68.75) | | Serous adenocarcinoma | 14 | 4 (14.81) | 10 (31.25) |
| | Pathological grade | 3.688 | 0.158 | | G1 | 15 | 10 (37.04) | 5 (15.63) | | G2 | 14 | 6 (22.22) | 8 (25.00) | | G3 | 30 | 11 (40.74) | 19 (76.67) |
| | DFI (months) | 16.076 | <0.001 | | <12 | 32 | 7 (25.93) | 25 (78.13) | | ≥12 | 27 | 20 (74.07) | 7 (21.87) |
| | Recurrence site | 3.543 | 0.060 | | Pelvic cavity | 25 | 15 (55.56) | 10 (31.25) | | Outside pelvic cavity | 34 | 12 (44.44) | 22 (68.75) |
| | Chemotherapy regimen | 14.019 | <0.001 | | Paclitaxel + platinum drugs | 40 | 25 (92.59) | 15 (46.88) | | Others | 19 | 2 (7.41) | 17 (53.12) |
| | Paclitaxel + platinum drug scheme | 0.293 | 0.589 | | Paclitaxel + cisplatin | 24 | 12 (44.44) | 12 (37.50) | | Paclitaxel + other platinum drugs | 35 | 15 (55.56) | 20 (62.50) |
|
|
